COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,731 Articles (22,502 medRxiv, 8,229 bioRxiv)

Most recent first Previous |  Page 1020: Articles 10191-10200  | Next

Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a retrospective cohort study
Kojima, Y., Nakakubo, S., Takei, N., Kamada, K., Yamashita, Y., Nakamura, J., Matsumoto, M., Sato, K., Horii, H., Shima, H., Suzuki, M., Konno, S.
10.1101/2021.12.13.21267717 — Posted: 2021-12-14
Mental Health During COVID-19: A Qualitative Study with Ethnically Diverse Healthcare Workers in the United Kingdom
Qureshi, I., Gogoi, M., Al-Oraibi, A., Wobi, F., Chaloner, J., Gray, L., Guyatt, A. L., Nellums, L., Pareek, M.
10.1101/2021.12.13.21267718 — Posted: 2021-12-14
COVID-19 vaccine effectiveness against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-linkage of national registries February-September 2021
Machado, A., Kislaya, I., Rodrigues, A. P., Sequeira, D., Lima, J., Cruz, C., Leite, P. P., Dias, C., Nunes, B.
10.1101/2021.12.10.21267619 — Posted: 2021-12-14
Differential impact of Covid-19 on incidence of diabetes mellitus and cardiovascular diseases in acute, post-acute and long Covid-19: population-based cohort study in the United Kingdom
Rezel-Potts, E., Douiri, A., Sun, X., Chowienczyk, P. J., Shah, A. M., Gulliford, M. C.
10.1101/2021.12.13.21267723 — Posted: 2021-12-14
Humoral and cellular immune responses and their kinetics vary in dependence of diagnosis and treatment in immunocompromised patients upon COVID-19 mRNA vaccination.
Wagner, A., Garner-Spitzer, E., Schoetta, A. M., Orola, M., Wessely, A., Zwazl, I., Ohradanova-Repic, A., Tajti, G., Gebetsberger, L., Kratzer, B., Tomosel, E., Kutschera, M., Tobudic, S., Pickl, W. W., Kundi, M., Stockinger, H., Novacek, G., Reinisch, W., Zielinski, C., Wiedermann, U.
10.1101/2021.12.13.21267603 — Posted: 2021-12-14
Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection
Shoham, S., Bloch, E. M., Casadevall, A., Hanley, D., Lau, B., Gebo, K., Cachay, E., Kassaye, S. G., Paxton, J. H., Gerber, J., Levine, A. C., Currier, J., Patel, B., Allen, E. S., Anjan, S., Appel, L., Baksh, S., Blair, P. W., Bowen, A., Broderick, P., Caputo, C. A., Cluzet, V., Cordisco, M. E., Cruser, D., Ehrhardt, S., Forthal, D., Fukuta, Y., Gawad, A., Gniadek, T., Hammel, J., Huaman, M. A., Jabs, D. A., Jedlicka, A., Karlen, N., Klein, S., Laeyendecker, O., Lane, K., McBee, N., Meisenberg, B., Merlo, C., Mosnaim, G., Park, H.-S., Pekosz, A., Petrini, J., Rausch, W., Shade, D. M., Shapiro, J., Singleton, J. R., Sutcliffe, C., Thomas, D. L., Yarava, A., Zand, M. S., Zenilman, J., Tobian, A. A. R., Sullivan, D. J.
10.1101/2021.12.13.21267611 — Posted: 2021-12-14
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination
Kaku, C. I., Champney, E., Normark, J., Johnson, C. E., Ahlm, C., Sakharkar, M., Ackerman, M. E., Forsell, M. N., Walker, L. M.
10.1101/2021.12.13.21267598 — Posted: 2021-12-14
Harmonization of SARS CoV-2 antibodies determination. Is it really possible?
Dittadi, R.
10.1101/2021.12.13.21267669 — Posted: 2021-12-14
Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study
Florea, A., Sy, L. S., Luo, Y., Qian, L., Bruxvoort, K. J., Ackerson, B. K., Lee, G. S., Ku, J. H., Tubert, J. E., Tian, Y., Talarico, C. A., Tseng, H. F.
10.1101/2021.12.13.21267620 — Posted: 2021-12-14
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N. S., Cohen, C., Kreiss, Y., Alroy-Preis, S., Regev-Yochay, G., Mendelson, E., Mandelboim, M.
10.1101/2021.12.13.21267670 — Posted: 2021-12-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).